[Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy]
- PMID: 9550744
[Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy]
Abstract
The cause of inflammatory bowel diseases is unknown, but T-cells play an important part in the pathogenesis of Crohn's disease. It was shown in recent years that activated T-cells produce certain cytokines that cause inflammation (interferon-alpha, tumour necrosis factor-alpha or TNF-alpha), but also cytokines (interleukin-10 or IL-10, transforming growth factor-alpha) which on the contrary inhibit inflammation. On the basis of this knowledge, the mucosal inflammatory reaction can be counteracted in a rational manner: antibodies against TNF-alpha in most patients with Crohn's disease who failed to respond to corticosteroids led to substantial reduction of disease activity. The first experiences with IL-10 treatment of Chrohn patients are also encouraging. It is expected that in the near future still more forms of immunotherapy directed against cytokines will become available.
Similar articles
-
Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.J Autoimmun. 2007 Sep-Nov;29(2-3):187-94. doi: 10.1016/j.jaut.2007.07.004. Epub 2007 Sep 5. J Autoimmun. 2007. PMID: 17804196
-
Immunological disorders in inflammatory bowel disease and immunotherapeutic implications.Ital J Gastroenterol Hepatol. 1999 May;31(4):313-25. Ital J Gastroenterol Hepatol. 1999. PMID: 10425578 Review.
-
Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.Curr Opin Gastroenterol. 2009 Jul;25(4):306-13. doi: 10.1097/MOG.0b013e32832bc627. Curr Opin Gastroenterol. 2009. PMID: 19448533 Review.
-
Regulation of gut inflammation and th17 cell response by interleukin-21.Gastroenterology. 2008 Apr;134(4):1038-48. doi: 10.1053/j.gastro.2008.01.041. Epub 2008 Jan 17. Gastroenterology. 2008. PMID: 18395085
-
[Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody].Nihon Rinsho. 2002 Mar;60(3):531-8. Nihon Rinsho. 2002. PMID: 11904969 Review. Japanese.
Cited by
-
BRD7 plays an anti-inflammatory role during early acute inflammation by inhibiting activation of the NF-кB signaling pathway.Cell Mol Immunol. 2017 Oct;14(10):830-841. doi: 10.1038/cmi.2016.31. Epub 2016 Jul 4. Cell Mol Immunol. 2017. PMID: 27374794 Free PMC article.
-
Polyphenol Extract of Moringa Oleifera Leaves Alleviates Colonic Inflammation in Dextran Sulfate Sodium-Treated Mice.Evid Based Complement Alternat Med. 2020 Nov 24;2020:6295402. doi: 10.1155/2020/6295402. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 33299453 Free PMC article.
-
Probiotics and inflammatory bowel disease.J R Soc Med. 2003 Apr;96(4):167-71. J R Soc Med. 2003. PMID: 12668702 Free PMC article. Review. No abstract available.